Keyword: Byetta


3. Victoza

As Sanofi’s Lantus has led the basal insulin field and Merck’s Januvia, the DPP-4 class, Novo Nordisk’s Victoza has been the dominant GLP-1 drug for years. Lately, however, its market share is on the wane, thanks to new rivals, particularly Eli Lilly’s Trulicity.
sanofi HQ

Report finds Sanofi GLP-1 med has safety edge over Victoza

Having just won an FDA nod for its GLP-1 diabetes contender Adlyxin, Sanofi will be going up against some entrenched rivals in its fight for market share. But new data from healthcare informatics firm Advera Health show it might have a safety edge over Novo Nordisk’s Victoza.